Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA)
CU Herborn, E Honold, M Wolf, J Kemper… - Investigative …, 2007 - journals.lww.com
CU Herborn, E Honold, M Wolf, J Kemper, S Kinner, G Adam, J Barkhausen
Investigative radiology, 2007•journals.lww.comObjective: The purpose of this study was to assess the diagnostic value and safety of the
contrast agent gadoterate meglumine (Gd-DOTA, DOTAREM, Guerbet, Roissy CdG Cedex,
France) in the setting of a postmarketing surveillance study. Materials and Methods:
Between January 2004 and October 2005, radiologists in 61 radiologic institutions were
asked to document the routine use of Gd-DOTA in a questionnaire. In addition to assessing
the image quality and diagnostic value of the contrast-enhanced magnetic resonance …
contrast agent gadoterate meglumine (Gd-DOTA, DOTAREM, Guerbet, Roissy CdG Cedex,
France) in the setting of a postmarketing surveillance study. Materials and Methods:
Between January 2004 and October 2005, radiologists in 61 radiologic institutions were
asked to document the routine use of Gd-DOTA in a questionnaire. In addition to assessing
the image quality and diagnostic value of the contrast-enhanced magnetic resonance …
Abstract
Objective:
The purpose of this study was to assess the diagnostic value and safety of the contrast agent gadoterate meglumine (Gd-DOTA, DOTAREM, Guerbet, Roissy CdG Cedex, France) in the setting of a postmarketing surveillance study.
Materials and Methods:
Between January 2004 and October 2005, radiologists in 61 radiologic institutions were asked to document the routine use of Gd-DOTA in a questionnaire. In addition to assessing the image quality and diagnostic value of the contrast-enhanced magnetic resonance imaging scans, we statistically evaluated and analyzed demographic and safety data.
Results:
A total of 24,308 patients were intravenously injected with Gd-DOTA for various diagnostic examinations. The examination allowed for establishing a diagnosis in> 99% of cases and image quality was rated as “excellent” or “good” in 97.5% of all cases. Adverse events were noted in only 0.4% of the examinations and were mostly rated as minor, such as feeling of warmth or taste alteration. There was one serious adverse event, albeit with complete recovery.
Conclusion:
This postmarketing surveillance study suggests diagnostic efficacy and a favorable clinical safety profile of Gd-DOTA in clinical practice.
Lippincott Williams & Wilkins